{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,8]],"date-time":"2024-09-08T10:13:23Z","timestamp":1725790403570},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[1993,1,1]],"date-time":"1993-01-01T00:00:00Z","timestamp":725846400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Surg Today"],"published-print":{"date-parts":[[1993]]},"DOI":"10.1007\/bf00308994","type":"journal-article","created":{"date-parts":[[2004,10,12]],"date-time":"2004-10-12T16:32:46Z","timestamp":1097598766000},"page":"13-20","source":"Crossref","is-referenced-by-count":2,"title":["The possible use of spleen cells for the adoptive immunotherapy of cancer patients"],"prefix":"10.1007","volume":"23","author":[{"given":"Mitsuo","family":"Katano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiro","family":"Kubota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsunari","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuya","family":"Matsuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumio","family":"Nagumo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeharu","family":"Hisatsugu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Katsuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jutaroh","family":"Tadano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"CR1","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1084\/jem.155.6.1823","volume":"155","author":"EE Grimm","year":"1982","unstructured":"Grimm EE, Mazumder A, Zhang HZ, Rosemberg SA (1982) The lymphokine-activated killer cell phenomenon: Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med 155:1823?1841","journal-title":"J Exp Med"},{"key":"CR2","doi-asserted-by":"crossref","first-page":"3117","DOI":"10.1001\/jama.1986.03380220083027","volume":"256","author":"MT Lotze","year":"1986","unstructured":"Lotze MT, Chang AE, Seipp CA, Simpson C, Vetto JT, Rosemberg SA (1986) High-dose recombinant interleukin 2 in the treatment of patients with disseminated cancer: Responses, treatment-related morbidity, and histologic findings. JAMA 256:3117?3124","journal-title":"JAMA"},{"key":"CR3","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1056\/NEJM198704093161501","volume":"316","author":"SA Rosemberg","year":"1987","unstructured":"Rosemberg SA, Lotze MT, Muul LM Chang AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT, Seipp CA, Simpson CG, White DE (1987) A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Eng J Med 316:889?897","journal-title":"N Eng J Med"},{"key":"CR4","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/0167-5699(88)91261-3","volume":"9","author":"SA Rosemberg","year":"1988","unstructured":"Rosemberg SA (1988) Immunotherapy of cancer using interleukin 2. Immunol Today 9:58?62","journal-title":"Immunol Today"},{"key":"CR5","first-page":"673","volume":"71","author":"A Uchida","year":"1983","unstructured":"Uchida A, Mickshe M (1983) Lysis of fresh human tumor cells by autologous peripheral blood lymphocytes and pleural effusion lymphocytes activated by OK-432. J Natl Cancer Inst 71:673?680","journal-title":"J Natl Cancer Inst"},{"key":"CR6","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/ijc.2910320107","volume":"32","author":"A Uchida","year":"1983","unstructured":"Uchida A, Mickshe M (1983) Lysis of fresh human tumor cells by autologous large granular lymphocytes from peripheral blood and pleural effusions. Int J Cancer 32:37?44","journal-title":"Int J Cancer"},{"key":"CR7","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1159\/000233510","volume":"74","author":"M Ley De","year":"1984","unstructured":"De Ley M, Claeys H (1984) Streptococcal preparation OK-432-induced interferon in human leukocytes: Purification and characterization. Int Arch Allergy Appl Immunol 74:21?28","journal-title":"Int Arch Allergy Appl Immunol"},{"key":"CR8","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/0192-0561(85)90035-9","volume":"7","author":"O Ichimura","year":"1985","unstructured":"Ichimura O, Suzuki S, Saito M, Sugawara Y, Ishida N (1985) Augumentation of interleukin 1 and interleukin 2 production by OK-432. Int J Immunopharmacol 7:263?270","journal-title":"Int J Immunopharmacol"},{"key":"CR9","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1007\/BF00205440","volume":"27","author":"M Katano","year":"1988","unstructured":"Katano M, Yamamoto H, Mizoguchi T, Hisatsugu T (1988) Induction of tumor growth inhibitory factor (TGIF) in human mononuclear cells by OK-432, a streptococcal preparation. Cancer Immunol Immunother 27:198?204","journal-title":"Cancer Immunol Immunother"},{"key":"CR10","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/0162-3109(86)90027-5","volume":"111","author":"A Yamamoto","year":"1986","unstructured":"Yamamoto A, Nagamuta M, Usami H, Sugawara Y, Watanabe N, Niitsu Y, Urushizaki I (1986) Release of tumor necrosis factor (TNF) into mouse peritoneal fluid by OK-432, a streptococcal preparation. Immunopharmacology 111:79?86","journal-title":"Immunopharmacology"},{"key":"CR11","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1007\/BF02470717","volume":"20","author":"M Katano","year":"1990","unstructured":"Katano M, Mizoguchi T, Yamamoto H, Nakamura M, Matsuo T, Hisatsugu T, Kisu T, Yamaoka K, Tokunaga O (1990) The antitumor effects of locally injecting human peripheral blood mononuclear cells treated with OK-432 into the tumor site: The possible role of a tumor growth inhibitory factor (TGIF). Jpn J Surg 20:76?82","journal-title":"Jpn J Surg"},{"key":"CR12","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/BF02470644","volume":"17","author":"T Toge","year":"1987","unstructured":"Toge T, Seto Y, Kuroi K, Yamada H, Aratani K, Fujita T, Yanagawa E, Hattori T (1987) Relationship of the distribution of Leu-2+ cells with suppressor cell activities in the spleen and lymph nodes from gastric cancer. Jpn J Surg 17:72?77","journal-title":"Jpn J Surg"},{"key":"CR13","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1007\/BF02471527","volume":"18","author":"E Yanagawa","year":"1988","unstructured":"Yanagawa E, Toge T, Sawamura A, Kegoya Y, Baba N, Hattori T (1988) The regulation of natural killer cell activity by splenic nonspecific suppressor cells and its modification in cancer patients. Jpn J Surg 18:660?667","journal-title":"Jpn J Surg"},{"key":"CR14","first-page":"967","volume":"84","author":"T Akiyoshi","year":"1983","unstructured":"Akiyoshi T, Koba F, Miyazaki S, Arinaga S, Tsuji H (1983) NK activity, TCGF production, and generation of cell-mediated cytotoxicity in spleen cells from gastric cancer patients (in Japanese with English Abstract). Nippon Geka Gakkai Zasshi 84:967?970","journal-title":"Nippon Geka Gakkai Zasshi"},{"key":"CR15","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.4049\/jimmunol.129.5.2282","volume":"129","author":"SC Miller","year":"1982","unstructured":"Miller SC (1982) Production and renewal of murine natural killer cells in the spleen and bone marrow. J Immunol 129:2282?2286","journal-title":"J Immunol"},{"key":"CR16","doi-asserted-by":"crossref","first-page":"518","DOI":"10.7326\/0003-4819-108-4-518","volume":"108","author":"RI Fisher","year":"1988","unstructured":"Fisher RI, Coltman CA, Doroshow JH, Rayner AA, Hawkins MJ, Mier JW, Wiernik P, Mcmannis JD, Weiss GR, Margolin KA, Gemlo BT, Hoth DF, Parkinson DR, Paietta E (1988) Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells: A phase II trial. Ann Intern Med 108:518?523","journal-title":"Ann Intern Med"},{"key":"CR17","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S0140-6736(89)91609-7","volume":"18","author":"RL Kradin","year":"1989","unstructured":"Kradin RL, Kurnick JT, Lazarus DS, Preffer FI, Dubinett SM, Pinto CE, Gifford J, Davidson E, Grove B, Callahan RJ (1989) Tumor-infiltrating lymphocytes and interleukin-2 in the treatment of advanced cancer. Lancet 18:577?580","journal-title":"Lancet"},{"key":"CR18","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJM198812223192527","volume":"319","author":"SA Rosemberg","year":"1988","unstructured":"Rosemberg SA, Packard BS, Aebersold PM, Solomon D, Toy ST, Simon P, Seipp CA, Simpson C, Charles C, Bock S, Schwartzentruber D, Wei JP, White DE (1988) Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma: A preliminary report. New Eng J Med 319:1676?1680","journal-title":"New Eng J Med"},{"key":"CR19","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1126\/science.3489291","volume":"233","author":"SA Rosemberg","year":"1986","unstructured":"Rosemberg SA, Spiess P, Lafreiere RL (1986) A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science (Washington) 233:1318?1321","journal-title":"Science"},{"key":"CR20","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.4049\/jimmunol.137.9.2814","volume":"137","author":"NK Damle","year":"1986","unstructured":"Damle NK, Doyle LV, Bradley EC (1986) Interleukin-2-activated human killer cells are derived from phenotypically heterogeneous precursors. J Immunol 137:2814?2822","journal-title":"J Immunol"},{"key":"CR21","doi-asserted-by":"crossref","first-page":"802","DOI":"10.4049\/jimmunol.134.2.802","volume":"134","author":"K Itoh","year":"1985","unstructured":"Itoh K, Tilden AB, Kumagai K, Balch CM (1985) Leu-11+ lymphocytes with natural killer (NK) activity are precursors of recombinant interleukin-2 (rIL2)-induced activated killer (AK) cells. J Immunol 134:802?807","journal-title":"J Immunol"},{"key":"CR22","first-page":"6353","volume":"47","author":"DS Heo","year":"1987","unstructured":"Heo DS, Whiteside TL, Johnson JT, Chen K, Barnes EL, Herberman RB (1987) Long-term interleukin-2-dependent growth and cytotoxic activity of tumor-infiltrating lymphocytes from human squamous cell carcinomas of the head and neck. Cancer Res 47:6353?6362","journal-title":"Cancer Res"},{"key":"CR23","first-page":"405","volume-title":"International symposium on new horizons in tumor immunotherapy","author":"M Katano","year":"1989","unstructured":"Katano M, Yamamoto H, Mizoguchi T, Iyama A, Matsuo T, Nakamura M, Hisatsugu T, Torisu M (1989) Induction of a tumor growth inhibitory factor (TGIF) in human mononuclear cells by OK-432. Possible clinical use of TGIF. In: Torisu M, Yoshida T (eds) International symposium on new horizons in tumor immunotherapy. Elsevier, Amsterdam, pp 405?416"},{"key":"CR24","unstructured":"Katano M, Yamamoto H, Matsuo T, Nakamura M, Mizoguchi T, Hisatsugu T (1989) Clinical significance of tumor growth inhibitory factor (TGIF). In: Proceedings of the 7th International Congress of Immunology, Berlin (abstract)"},{"key":"CR25","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/BF02172074","volume":"2","author":"M Katano","year":"1990","unstructured":"Katano M, Yamamoto H, Nakamura M, Matsuo T, Hisatsugu T (1990) Synergistic effects of TGIF and interferon ? (IFN ?) on tumor growth. Biotherapy 2:33?40","journal-title":"Biotherapy"}],"container-title":["Surgery Today"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00308994.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF00308994\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00308994","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,29]],"date-time":"2023-04-29T14:48:00Z","timestamp":1682779680000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF00308994"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1993]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[1993]]}},"alternative-id":["BF00308994"],"URL":"https:\/\/doi.org\/10.1007\/bf00308994","relation":{},"ISSN":["0941-1291","1436-2813"],"issn-type":[{"value":"0941-1291","type":"print"},{"value":"1436-2813","type":"electronic"}],"subject":[],"published":{"date-parts":[[1993]]}}}